Back

HIMS Stock

Live symbol workspace

HIMS market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $19.15
Trend Flat
Sentiment Neutral

Price Chart

📈
Loading chart for HIMS...
Powered by TradingView
{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support
$18.19
Resistance
$20.11

Volume & Momentum

Volume
Weak
0.8x avg
Momentum
0%
Weak

Technical Context

Current price
$19.15
RSI context
50

Market Sentiment

50
Neutral

Stock Metrics

Daily Vol
0%
VIX Est
20
Weekly
0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%
— 0.0 pts vs previous week
Avg confidence across 6 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

HIMS News Intelligence (15 articles)

AI-curated news influencing HIMS price, sentiment, and trend

Explore All HIMS News with AI Analysis
Economy
2 months, 4 weeks ago

Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.

Impact on HIMS: Neutral market sentiment indicated
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)
View full analysis →
Yahoo Finance 94% confidence
Stocks
3 months ago

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping …

Impact on HIMS: Neutral market sentiment indicated
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)
View full analysis →
CNBC 94% confidence
Economy
3 months ago

Hims stock gains as FDA reviews peptides, Voyager secures NASA contract

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock …

Impact on HIMS: Neutral market sentiment indicated
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)
View full analysis →
Yahoo Finance 94% confidence
🤖

AI Analysis

Multi-Provider AI Analysis

Neutral

AI Summary

Loading...

Confidence
0%
AI Model Multi-Provider AI Analysis
Open article